{"id":"intradermal-vaccine","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Local injection site reactions (erythema, induration, pruritus)"},{"rate":"5-15","effect":"Mild systemic symptoms (myalgia, fatigue)"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Intradermal administration targets the dermis, which is rich in antigen-presenting cells and immune effector cells, allowing for more efficient antigen presentation and T-cell activation. This route can reduce the required antigen dose while maintaining or improving immune response, and may enhance both cellular and humoral immunity depending on the vaccine formulation.","oneSentence":"Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:29.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention (intradermal formulations)"},{"name":"Tuberculosis prevention (BCG and experimental TB vaccines)"},{"name":"Other infectious diseases via intradermal route (varies by specific vaccine)"}]},"trialDetails":[{"nctId":"NCT05642429","phase":"PHASE1","title":"Study of AV-1959D, an Amyloid Beta Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute for Molecular Medicine","startDate":"2023-02-27","conditions":"Alzheimer Disease","enrollment":48},{"nctId":"NCT07478952","phase":"PHASE1","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-17","conditions":"Epstein-Barr Virus","enrollment":120},{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT06257212","phase":"PHASE4","title":"Live Vaccines and Innate Immune Training in COPD.","status":"COMPLETED","sponsor":"Josefin Eklöf","startDate":"2024-02-28","conditions":"Trained Innate Immunity, COPD","enrollment":60},{"nctId":"NCT05879965","phase":"","title":"Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-10-06","conditions":"Monkeypox","enrollment":345},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT06254326","phase":"PHASE1","title":"ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-09-19","conditions":"Recurrent Oligodendroglioma, Progressive Oligodendroglioma","enrollment":12},{"nctId":"NCT06272812","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-02-19","conditions":"Tuberculosis (TB)","enrollment":5500},{"nctId":"NCT03384914","phase":"PHASE2","title":"Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-02-19","conditions":"Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I","enrollment":119},{"nctId":"NCT06962904","phase":"PHASE1","title":"CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2025-07-07","conditions":"Rotavirus Infections","enrollment":50},{"nctId":"NCT06253494","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-14","conditions":"Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium","enrollment":60},{"nctId":"NCT05591339","phase":"PHASE4","title":"Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2023-12-01","conditions":"Diabetes Mellitus, BCG Vaccination Reaction","enrollment":200},{"nctId":"NCT04658680","phase":"PHASE4","title":"Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2021-02-25","conditions":"Infant Mortality, BCG","enrollment":22800},{"nctId":"NCT07394426","phase":"EARLY_PHASE1","title":"A Phase I Study of PepGNP-ChikV in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Gylden Pharma Ltd","startDate":"2026-08-03","conditions":"Chikungunya, Chikungunya Fever, Chikungunya Virus Infection","enrollment":40},{"nctId":"NCT03334305","phase":"PHASE1","title":"Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-05-16","conditions":"Malignant Glioma, High Grade Glioma","enrollment":18},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT03096093","phase":"PHASE1, PHASE2","title":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Vaccines Limited","startDate":"2017-04-25","conditions":"Cancer, Neoplasms","enrollment":34},{"nctId":"NCT06837116","phase":"EARLY_PHASE1","title":"Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2025-04-19","conditions":"Dengue","enrollment":29},{"nctId":"NCT07345208","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of ID vs IM Rabies Vaccine","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-12-15","conditions":"Rabies","enrollment":90},{"nctId":"NCT07020715","phase":"PHASE2","title":"A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-03-01","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT06514898","phase":"PHASE1","title":"Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-05-05","conditions":"Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma","enrollment":12},{"nctId":"NCT06845358","phase":"PHASE1","title":"Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-11-26","conditions":"Tuberculosis","enrollment":""},{"nctId":"NCT06670755","phase":"NA","title":"ID93/GLA-SE Vaccination + BCG Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-12-18","conditions":"Tuberculosis","enrollment":48},{"nctId":"NCT02451982","phase":"PHASE2","title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03-28","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT03767582","phase":"PHASE1, PHASE2","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-12","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":46},{"nctId":"NCT06782932","phase":"PHASE1, PHASE2","title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-05-27","conditions":"Pancreatic Cancer","enrollment":38},{"nctId":"NCT06246851","phase":"NA","title":"BCG Revaccination Study in Diabetic and Non-Diabetic Adults","status":"ENROLLING_BY_INVITATION","sponsor":"University of Oxford","startDate":"2024-04-03","conditions":"Tuberculosis","enrollment":36},{"nctId":"NCT05654883","phase":"","title":"New York City Observational Study of Mpox Immunity","status":"ENROLLING_BY_INVITATION","sponsor":"NYU Langone Health","startDate":"2022-11-11","conditions":"Monkeypox, Mpox, HIV","enrollment":174},{"nctId":"NCT03396575","phase":"PHASE1","title":"Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)","status":"TERMINATED","sponsor":"University of Florida","startDate":"2018-07-17","conditions":"Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma","enrollment":11},{"nctId":"NCT02346747","phase":"PHASE2","title":"A Trial of Vigil for Participants With Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gradalis, Inc.","startDate":"2015-02","conditions":"Ovarian Cancer, Ovarian Neoplasms","enrollment":92},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT05329532","phase":"PHASE1, PHASE2","title":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","status":"RECRUITING","sponsor":"Scancell Ltd","startDate":"2022-04-07","conditions":"Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma","enrollment":168},{"nctId":"NCT06175221","phase":"PHASE2","title":"Autologous TLPO Vaccine Basket","status":"TERMINATED","sponsor":"Elios Therapeutics, LLC","startDate":"2023-11-29","conditions":"Tumor, Solid, Tumor Metastasis, Cancer","enrollment":63},{"nctId":"NCT06715605","phase":"PHASE2","title":"A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS","status":"WITHDRAWN","sponsor":"University Hospital, Antwerp","startDate":"2025-04-30","conditions":"Multiple Sclerosis","enrollment":""},{"nctId":"NCT03018288","phase":"PHASE2","title":"Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-09-21","conditions":"Glioblastoma","enrollment":90},{"nctId":"NCT05507671","phase":"PHASE3","title":"The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2021-05-27","conditions":"COVID-19","enrollment":556},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48},{"nctId":"NCT04523688","phase":"PHASE2","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2021-03-25","conditions":"Glioblastoma, Vaccination","enrollment":28},{"nctId":"NCT03718130","phase":"PHASE1","title":"Combination HTNV and PUUV DNA Vaccine","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2019-07-10","conditions":"Hantaan Virus Disease, Puumala Virus","enrollment":61},{"nctId":"NCT06195618","phase":"PHASE1","title":"Personalized Vaccine for TNBC Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2025-08-01","conditions":"Breast Cancer Female","enrollment":8},{"nctId":"NCT06067555","phase":"EARLY_PHASE1","title":"Intradermal Influenza Vaccination","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-01-24","conditions":"Vaccine Reaction","enrollment":249},{"nctId":"NCT01309230","phase":"PHASE2","title":"A Trial of FANG™ Vaccine for Participants With Ovarian Cancer","status":"COMPLETED","sponsor":"Gradalis, Inc.","startDate":"2011-03-08","conditions":"Ovarian Cancer","enrollment":39},{"nctId":"NCT06997367","phase":"PHASE2","title":"Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)","status":"RECRUITING","sponsor":"Bharat Biotech International Limited","startDate":"2025-03-01","conditions":"Tuberculosis (TB)","enrollment":164},{"nctId":"NCT03548064","phase":"PHASE1","title":"A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-10","conditions":"Gastroenteritis Escherichia Coli, Immunisation","enrollment":75},{"nctId":"NCT05952934","phase":"PHASE2","title":"Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2024-02-12","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":100},{"nctId":"NCT04078269","phase":"PHASE1","title":"MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2019-08-26","conditions":"Non-small Cell Lung Cancer","enrollment":6},{"nctId":"NCT01326104","phase":"PHASE2","title":"Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor","status":"COMPLETED","sponsor":"University of Florida","startDate":"2010-09-07","conditions":"Medulloblastoma, Neuroectodermal Tumor","enrollment":26},{"nctId":"NCT05964361","phase":"PHASE1, PHASE2","title":"First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-12-06","conditions":"Esophageal Cancer, Pancreas Cancer, Ovarian Cancer","enrollment":10},{"nctId":"NCT05512949","phase":"PHASE2","title":"Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-09-09","conditions":"Monkeypox","enrollment":229},{"nctId":"NCT06919796","phase":"PHASE2","title":"mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes","status":"NOT_YET_RECRUITING","sponsor":"PharmaJet, Inc.","startDate":"2025-05-01","conditions":"Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2","enrollment":40},{"nctId":"NCT04235257","phase":"PHASE4","title":"Intradermal, Fractional Dose of HPV Vaccines:","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2020-11-01","conditions":"HPV Infection, HPV Vaccine","enrollment":40},{"nctId":"NCT05460377","phase":"PHASE4","title":"Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-07-26","conditions":"Poliomyelitis","enrollment":1224},{"nctId":"NCT06078891","phase":"EARLY_PHASE1","title":"Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?","status":"ENROLLING_BY_INVITATION","sponsor":"Tamir Ben-Hur","startDate":"2023-07-01","conditions":"Alzheimer Disease, Late Onset","enrollment":60},{"nctId":"NCT03382977","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","status":"RECRUITING","sponsor":"VBI Vaccines Inc.","startDate":"2017-12-06","conditions":"Glioblastoma Multiforme","enrollment":98},{"nctId":"NCT03947190","phase":"PHASE2","title":"A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2022-08-31","conditions":"Malaria,Falciparum","enrollment":80},{"nctId":"NCT05113862","phase":"PHASE1","title":"A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2","status":"COMPLETED","sponsor":"Gylden Pharma Ltd","startDate":"2022-01-10","conditions":"Coronavirus, SARS-CoV-2 Infection, COVID-19","enrollment":26},{"nctId":"NCT04975178","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Biofabri, S.L","startDate":"2022-10-17","conditions":"Tuberculosis","enrollment":7120},{"nctId":"NCT04884308","phase":"PHASE2","title":"Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-04-28","conditions":"Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria","enrollment":30},{"nctId":"NCT04777721","phase":"PHASE1","title":"Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-17","conditions":"Tuberculosis","enrollment":12},{"nctId":"NCT03953196","phase":"EARLY_PHASE1","title":"A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT04251117","phase":"PHASE1, PHASE2","title":"GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geneos Therapeutics","startDate":"2020-03-01","conditions":"HCC","enrollment":36},{"nctId":"NCT02589795","phase":"PHASE1","title":"Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-08-11","conditions":"HIV","enrollment":28},{"nctId":"NCT01814813","phase":"PHASE2","title":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-06-19","conditions":"Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma","enrollment":90},{"nctId":"NCT03153410","phase":"EARLY_PHASE1","title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-27","conditions":"Pancreatic Cancer","enrollment":11},{"nctId":"NCT01973322","phase":"PHASE2","title":"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized \"Proof-of-principle\" Phase II Study","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-10-08","conditions":"Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV","enrollment":34},{"nctId":"NCT02618902","phase":"PHASE1","title":"A \"negative\"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2017-05-30","conditions":"Multiple Sclerosis","enrollment":9},{"nctId":"NCT04806178","phase":"PHASE3","title":"Immunological Response of Bladder Cancer Patients Under BCG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2021-09-03","conditions":"Bladder Cancer, Bacillus Calmette-Guerin","enrollment":30},{"nctId":"NCT03101267","phase":"PHASE2","title":"A Dose-finding Study of ASP4070","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-04-13","conditions":"Rhinitis, Allergic, Seasonal","enrollment":150},{"nctId":"NCT02469688","phase":"PHASE1","title":"A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-06-18","conditions":"Cedar Pollinosis","enrollment":66},{"nctId":"NCT02851277","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-12-13","conditions":"Peanut Allergy","enrollment":31},{"nctId":"NCT03755713","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2019-03-12","conditions":"Peanut Allergy","enrollment":20},{"nctId":"NCT06636682","phase":"PHASE2","title":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Cellvax Therapeutics Inc","startDate":"2024-10-14","conditions":"Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers","enrollment":100},{"nctId":"NCT04169009","phase":"PHASE4","title":"Persistence of Protection by Shingrix","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-07-28","conditions":"Herpes Zoster","enrollment":105},{"nctId":"NCT05142319","phase":"PHASE4","title":"Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2021-10-12","conditions":"COVID-19","enrollment":326},{"nctId":"NCT04348370","phase":"PHASE4","title":"BCG Vaccine for Health Care Workers as Defense Against COVID 19","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2020-04-20","conditions":"Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere","enrollment":659},{"nctId":"NCT05641545","phase":"PHASE1","title":"IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients","status":"TERMINATED","sponsor":"SLK Kliniken Heilbronn GmbH","startDate":"2022-10-17","conditions":"Advanced Renal Cell Carcinoma","enrollment":1},{"nctId":"NCT01538940","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2011-11-01","conditions":"Influenza","enrollment":415},{"nctId":"NCT02649582","phase":"PHASE1, PHASE2","title":"Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2015-12","conditions":"Glioblastoma Multiforme of Brain","enrollment":20},{"nctId":"NCT04166006","phase":"PHASE2","title":"A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2019-12-12","conditions":"Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma","enrollment":51},{"nctId":"NCT03879512","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG","status":"COMPLETED","sponsor":"Wuerzburg University Hospital","startDate":"2018-02-07","conditions":"Childhood Glioblastoma","enrollment":24},{"nctId":"NCT04327206","phase":"PHASE3","title":"BCG Vaccination to Protect Healthcare Workers Against COVID-19","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2020-03-30","conditions":"Coronavirus Disease 2019 (COVID-19), Respiratory Illness, Corona Virus Infection","enrollment":6828},{"nctId":"NCT02919644","phase":"PHASE2","title":"Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-12-02","conditions":"Stage IV Colorectal Cancer, Curative Resection","enrollment":19},{"nctId":"NCT04542330","phase":"PHASE3","title":"Using BCG to Protect Senior Citizens During the COVID-19 Pandemic","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2020-09-15","conditions":"Covid19, Non-specific Effects of Vaccines, Heterologous Immunity","enrollment":1700},{"nctId":"NCT03371485","phase":"PHASE1","title":"AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2018-05-29","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":9},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT01446731","phase":"PHASE2","title":"Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2011-10","conditions":"Prostatic Neoplasms","enrollment":43},{"nctId":"NCT01803152","phase":"PHASE1","title":"Dendritic Cell Vaccine for Children and Adults With Sarcoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2014-01-06","conditions":"Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma","enrollment":19},{"nctId":"NCT05163223","phase":"PHASE2","title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer","status":"TERMINATED","sponsor":"Aston Sci. Inc.","startDate":"2022-02-28","conditions":"Breast Cancer","enrollment":10},{"nctId":"NCT05522296","phase":"","title":"Break-through Infection Following Mpox vaccinatIon","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2022-09-12","conditions":"Mpox","enrollment":3125},{"nctId":"NCT06142461","phase":"PHASE2","title":"Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System","status":"WITHDRAWN","sponsor":"PharmaJet, Inc.","startDate":"2024-05-31","conditions":"Vaccine Reaction","enrollment":""},{"nctId":"NCT06002503","phase":"PHASE1","title":"Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaJet, Inc.","startDate":"2023-10-16","conditions":"Vaccine Reaction","enrollment":46},{"nctId":"NCT05765084","phase":"PHASE1, PHASE2","title":"Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-02-24","conditions":"Malignant Pleural Mesothelioma","enrollment":15},{"nctId":"NCT00135629","phase":"PHASE3","title":"Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2002-10","conditions":"Rhinitis, Allergic, Seasonal","enrollment":18},{"nctId":"NCT04911621","phase":"PHASE1, PHASE2","title":"Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2021-09-10","conditions":"High Grade Glioma, Diffuse Intrinsic Pontine Glioma","enrollment":10},{"nctId":"NCT03927222","phase":"PHASE2","title":"Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma","status":"TERMINATED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2019-09-30","conditions":"Glioblastoma","enrollment":6},{"nctId":"NCT05977127","phase":"PHASE2","title":"Intradermal Administration of a COVID-19 mRNA Vaccine in Elderly","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2023-09-26","conditions":"Vaccination; Infection, COVID-19","enrollment":48},{"nctId":"NCT05406908","phase":"PHASE4","title":"Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2022-06-15","conditions":"Bullous Dermatoses, Psoriasis, COVID-19 Vaccines","enrollment":109},{"nctId":"NCT05475106","phase":"EARLY_PHASE1","title":"Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms","status":"RECRUITING","sponsor":"Instituto de Medicina Regenerativa","startDate":"2022-05-12","conditions":"Neoplasms","enrollment":100},{"nctId":"NCT04509167","phase":"EARLY_PHASE1","title":"Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms","status":"COMPLETED","sponsor":"Instituto de Medicina Regenerativa","startDate":"2020-08-10","conditions":"Neoplasms","enrollment":30},{"nctId":"NCT03418480","phase":"PHASE1, PHASE2","title":"HARE-40: HPV Anti-CD40 RNA vaccinE","status":"COMPLETED","sponsor":"University of Southampton","startDate":"2017-04-11","conditions":"Human Papilloma Virus Related Carcinoma, Head and Neck Neoplasm, Cervical Neoplasm","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":136,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intradermal vaccine","genericName":"Intradermal vaccine","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration. Used for Influenza prevention (intradermal formulations), Tuberculosis prevention (BCG and experimental TB vaccines), Other infectious diseases via intradermal route (varies by specific vaccine).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}